George Imvrios, Vasilios Papanikolaou, Miltiadis Lalountas, Kaliopi Patsiaoura, Dimitrios Giakoustidis, Ioannis Fouzas, Eva Anagnostara, Nikolaos Antoniadis, Dimitrios Takoudas – 28 June 2007 – Approximately 60 cases of biliary papillomatosis have been reported in the world literature, while only 6 cases have been reported to be treated with liver transplantation.
Laura Cisneros, Maria‐Carlota Londoño, Carmen Blasco, Ramón Bataller, Rosa Miquel, Miquel Bruguera, Pere Ginès, Antoni Rimola – 28 June 2007 – The pathogenic mechanisms of accelerated graft fibrosis in hepatitis C recurrence after liver transplantation (LT) are not well established. The aim of the study was to assess whether a greater activation of hepatic stellate cells (HSC), the major collagen‐producing cells in the liver, can occur in these patients as compared to non‐LT patients with chronic hepatitis C.
Caroline Créput, Frederique Blandin, Benjamin Deroure, Bruno Roche, Faouzi Saliba, Bernard Charpentier, Didier Samuel, Antoine Durrbach – 28 June 2007 – Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression after liver transplantation. However, CNI treatment is frequently associated with chronic renal failure (CRF). The reduction or interruption of CNI may reduce renal failure.
Sammy Saab, Mina K. Oh, Ayman B. Ibrahim, Francisco Durazo, Steven Han, Hasan Yersiz, Douglas G. Farmer, R. Mark Ghobrial, Leonard I. Goldstein, Myron J. Tong, Ronald W. Busuttil – 28 June 2007 – Adherence to antiviral therapy is essential to achieve sustained virological responses in patients treated for hepatitis C. An important limitation to use of appropriate doses of ribavirin is development of anemia. The aim of this study is to identify risk factors associated with anemia in liver transplant recipients undergoing treatment for recurrent hepatitis C virus (HCV).
Thomas Soliman, Hubert Hetz, Christoph Burghuber, Georg Györi, Gerd Silberhumer, Rudolf Steininger, Ferdinand Mühlbacher, Gabriela A. Berlakovich – 28 June 2007 – The appropriate time point for starting immunosuppressive treatment with calcineurin inhibitors after orthotopic liver transplantation (OLT) has been a subject of debate. The aim of the study was to analyze the effects of anti‐thymocyte globulin (ATG) induction therapy on rejection, renal function, infection, tumor rate, and survival.
28 June 2007
Obaid S. Shaikh, A. Jake Demetris – 28 June 2007
Tetsuro Sakai, Raymond M. Planinsic, Ibetsam A. Hilmi, J. Wallis Marsh – 28 June 2007 – Percutaneous large bore cannula placement during orthotopic liver transplantation (OLT) for use in venovenous bypass (VVB) has been reported to be a rapid and simple technique. It is, however, a technique that carries its own risks. The aim of the study was to investigate the incidence of complications related to the placement of a percutaneous venous return cannula and subsequent VVB in OLT.
A. Ríos, P. Ramírez, M.M. Rodríguez, L. Martínez, J.M. Rodríguez, P.J. Galindo, P. Parrilla – 28 June 2007 – In Spain, despite its high rate of cadaveric donation, death while on the liver transplant waiting list is high. For this reason, living liver donation is being encouraged despite of the risk of morbidity for the donor. The objective of this study was to analyze attitudes toward living liver donation among hospital personnel in a hospital with a recently authorized living donor liver transplantation program.
Ian N. Hines, Michael Kremer, Fuyumi Isayama, Ashley W. Perry, Richard J. Milton, April L. Black, Christy L. Byrd, Michael D. Wheeler – 27 June 2007 – The regeneration of liver tissue following transplantation is often complicated by inflammation and tissue damage induced by a number of factors, including ischemia and reperfusion injury and immune reactions to the donor tissue. The purpose of the current study is to characterize the effects of T cell–mediated hepatitis induced by concanavalin A (ConA) on the regenerative response in vivo.